Abstract: A method for specifically removing or isolating plasmin(ogen) or plasmin in presence of fibrinogen from a mixture containing plasmin(ogen) or plasmin by contacting the mixture with a rigid amino acid wherein the amino group of the amino acid and the carboxylic group of the amino acid are about 6-8 Angstroms, preferably about 7 Angstroms apart and the rigid amino acid is covalently bound to the support via the amino group of the amino acid.
Abstract: The invention provides compositions (e.g., kits) and methods for determine the number of bacteria and other microbes in samples having low concentrations of microbes, for use, e.g., in biological warfare defense, microbe detection and agricultural and environmental sciences.
Type:
Grant
Filed:
May 11, 2007
Date of Patent:
October 22, 2013
Assignee:
San Diego State University (SDSU) Foundation
Abstract: The invention relates generally to blood substitute solutions and methods for using blood substitute solutions. The solutions may be used in a variety of applications and are particularly suited for use in applications where at least a portion of a host's blood is replaced with a substitute solution.
Type:
Grant
Filed:
February 10, 2009
Date of Patent:
October 22, 2013
Assignees:
President and Fellows of Harvard College, The United States of America as Represented by the Department of Veterans Affairs
Abstract: A method of identifying a non-anticoagulant sulfated polysaccharide (NASP) which is capable of enhancing blood coagulation in dependence of FXI, the method comprising: a) combining a blood or plasma sample having activation competent FXI with a sulfated polysaccharide and measuring the clotting or thrombin generation parameters of the blood or plasma sample; b) combining a corresponding blood or plasma sample deficient In activation competent FXI with a sulfated polysaccharide and measuring the clotting or thrombin generation parameters of the blood or plasma sample and c) comparing the clotting or thrombin generation parameters of the blood or plasma samples as determined in steps (a) and (b) with each other.
Type:
Grant
Filed:
August 21, 2009
Date of Patent:
October 1, 2013
Assignees:
Baxter International Inc., Baxter Healthcare S.A.
Inventors:
Michael Dockal, Friedrich Scheiflinger, Peter Turecek
Abstract: The present invention relates to the use of matrix metalloproteinase MMP-10 in the preparation of a pharmaceutical composition useful for thrombolytic therapy, it also being possible for said composition to contain a plasminogen activator. Additionally, the present invention relates to said pharmaceutical composition for the treatment of thrombotic disorders.
Type:
Grant
Filed:
August 23, 2010
Date of Patent:
September 24, 2013
Assignee:
Proyecto de Biomedicina Cima, S.L.
Inventors:
Josune Orbe Lopategui, Jose Antonio Rodriguez Garcia, Jose Antonio Paramo Fernandez, Rosario Serrano Vargas
Abstract: The invention relates to a method for measuring the plasmine activity of microparticles, in particular circulating microparticles, in a sample of a biological fluid, particularly a biological fluid in a flow situation, wherein said method can be used as a diagnosis method or a method for following a treatment.
Type:
Grant
Filed:
June 6, 2008
Date of Patent:
September 24, 2013
Assignees:
Institut National de la Sante et de la Recherche Medicale (Inserm), Assistance Publique—Hopitaux de Marseille, Universite d'Aix-Marseille, Universite de caen Basse-Normandie
Abstract: Process for the stabilization of blood plasma components in a lyophilizate, wherein in a freeze-drying process, said blood plasma components were in a solution containing at least two different pH-lowering substances causing a predetermined pH value range to be adjusted in the solution formed upon reconstitution.
Type:
Grant
Filed:
February 15, 2008
Date of Patent:
August 27, 2013
Assignee:
Octapharma AG
Inventors:
Kim Bjornstrup, Martin Kern, Andrea Heger, Gerhard Gruber, Hans Sachse, Raimund Schuetz, Juergen Roemisch, Tor-Einar Svae
Abstract: The present invention provides a liver preservation solution containing trehalose and dibutyryl-cAMP. The content of nitroglycerin in the preservation solution is preferably lower than 0.44 mM. In the liver preservation solution of the present invention, since the toxicity due to nitroglycerin, which is observed during liver preservation, has been improved, liver transplantation can be performed with a high engrafted rate.
Abstract: Fixed-dried blood cells carrying an active agent are described, along with methods of making the same, methods of using the same, and compositions containing the same. The blood cells are preferably blood platelets.
Type:
Grant
Filed:
September 28, 2007
Date of Patent:
July 23, 2013
Assignee:
The University of North Carolina at Chapel Hill
Inventors:
Timothy C. Nichols, Thomas Fischer, Marjorie S. Read
Abstract: The present invention provides processes for preparing freeze-dried platelets, freeze-dried platelets made by those processes, platelets reconstituted from those freeze-dried platelets, methods of using the platelets for therapeutic, diagnostic, and research purposes, and kits comprising the freeze-dried platelets.
Type:
Grant
Filed:
August 12, 2005
Date of Patent:
July 16, 2013
Assignee:
Cellphirc, Inc
Inventors:
David Ho, Cindy S. Orser, Alan S. Rudolph, Keith Moskowitz, Joshua Dee
Abstract: Protein concentrates and protein isolates, in addition to processes for the production of protein concentrates and protein isolates, are disclosed. In particular, the disclosure relates to the removal of fiber from macroalgae and/or microalgae using low g-force centrifugation.
Abstract: The present invention relates to a method and composition for the cryopreservation of adipose tissue with the intention to use this tissue in the culturing of stem and/or progenitor cells. The method uses a specific cryoprotection medium to prevent damage of the original tissue during the cryopreservation while still maintaining a high viability of the stem and/or progenitor cells obtained from the cryopreserved adipose tissue. Furthermore the cryoprotection medium of the present invention does not contain any kind of xenogeneic sera, a critical factor since it is the intention of that the cryopreserved tissue is used for obtaining stem and/or progenitor cells that can be used in medicine. The cryoprotection medium is characterized in that it is a solution of physiological water comprising glycerol and sucrose and/or trehalose and optionally serum albumin.
Type:
Grant
Filed:
March 19, 2009
Date of Patent:
July 9, 2013
Assignee:
Cryo-Save AG
Inventors:
Guy Wouters, Kelly van Wemmel, Peter de Waele
Abstract: The present invention relates to methods for removing antiplatelet agents and anticoagulants from a platelet preparation. In one embodiment, the method includes the step of flowing the platelet preparation through a filtering tube comprising a filtering membrane and separating the antiplatelet agents and anticoagulants from the platelet preparation by tangential flow filtration. In another embodiment, the method includes the step of passing the platelet preparation through porous material that specifically binds to the antiplatelet agents and anticoagulants.
Abstract: A producing method for a living organism-applicable hydrogen-contained fluid, which includes hydrogen molecules in living organism-applicable fluid enclosed in a container (2i) with hydrogen molecule permeability, is provided. This method includes a hydrogen exposing step of exposing hydrogen molecules to the container (2i) in which the living organism-applicable fluid is enclosed from the outside of the container without opening the container. The container with hydrogen molecule permeability is one that allows a dissolved hydrogen concentration of a normal saline solution to be 1 ppb or greater when the container filled with the normal saline solution is immersed for 5 hours in a volume of hydrogen water, which stably maintains an approximately saturated state (1.6 ppm at 20 C degrees under 1 barometric pressure) and is 20 times the content volume of the container.
Abstract: Method for preserving tissue including immersing the tissue in a solution having a cryoprotectant concentration of at least 75% by weight, a cooling step where the tissue is cooled to a temperature between the glass transition temperature of the solution having a cryoprotectant concentration of at least 75% by weight and ?20° C., a storage step where the tissue is stored at a temperature between the glass transition temperature of the solution and ?20° C., a rewarming step, where the tissue is warmed, and a washing step.
Type:
Grant
Filed:
February 23, 2010
Date of Patent:
May 14, 2013
Assignees:
Lifeline Scientific, Inc., Cell & Tissue Systems, Inc.
Abstract: The present invention relates to methods for preserving platelet. In one embodiment, the method includes the steps of mixing platelets with a platelet preservation composition to form a platelet preparation, storing the platelet preparation for a desired period of time, and removing the antiplatelet agent and the anticoagulant from the platelet preparation by diafiltration prior to transfusion of the platelets. The platelet preservation composition comprises an effective amount of an antiplatelet agent and an effective amount of an anticoagulant.
Abstract: The present invention relates to a method for improving post-thaw survival of cryopreserved biological material comprising applying hydrostatic pressure to said biological material; keeping the said biological material at the hydrostatic pressure for a predetermined time period; releasing the hydrostatic pressure; and freezing the said biological material using any protocol applicable thereto.
Abstract: An organ perfusion apparatus and method monitor, sustain and/or restore viability of organs and preserve organs for storage and/or transport. Other apparatus include an organ transporter, an organ cassette and an organ diagnostic device. The method includes perfusing the organ at hypothermic and/or normothermic temperatures. The methods further include perfusing the organ at hypothermic and/or normothermic temperatures with a second perfusate containing a substance for reacting with the organ. Condition of the organ may be automatically monitored, and the perfusion process can be automatically controlled using a control program.
Abstract: Tissue solubilizing compositions are provided. The compositions comprise 3-(decyl dimethyl ammonio) propane sulfonate and polyethylene glycol dodecyl ether, such as tetraethylene glycol dodecyl ether. The compositions may be useful to solubilize tissue, including skin, mucosal membrane, and other tissue. The compositions may be further useful to preserve and recover analytes contained within the solubilized skin, mucosal membrane, and other tissue.
Type:
Grant
Filed:
April 27, 2011
Date of Patent:
March 5, 2013
Inventors:
Samir Mitragotri, Sumit Paliwal, Makoto Ogura, Russell M. Lebovitz
Abstract: A prognostic assay and kit and method of use thereof are provided. The kit and assay are used to determine the likelihood of a diseased cell or tissue having a therapeutic response to treatment with a cardiac glycoside in a disease having an etiology associated with excessive cell proliferation. The kit and assay are used to determine the ratio of isoforms of the ? subunit of Na, K-ATPase obtained from the diseased cell or tissue. The kit can be used to predict the therapeutic responsiveness of cancer or tumor in a subject to treatment with a cardiac glycoside. The kit and assay can be incorporated in a method of treating a disease or disorder having an etiology associated with excessive cell proliferation with a composition comprising a cardiac glycoside.
Type:
Grant
Filed:
May 4, 2010
Date of Patent:
February 5, 2013
Assignee:
Phoenix Biotechnology, Inc.
Inventors:
Otis Crandell Addington, Robert A. Newman, Peiying Yang